ADHD is associated with higher risk of premature mortality in population studies, but the reasons are multifactorial. The evidence does not support reducing the association to stress, trauma, personality, or a single biological mechanism.
The 2025 UK Life-Expectancy Study
A large matched cohort study used primary-care records from 792 UK practices. It identified 30,039 adults with diagnosed ADHD and 300,390 matched comparison participants from records spanning 2000–2019.
The estimated difference in life expectancy was:
- 6.78 fewer years for men with diagnosed ADHD compared with matched men
- 8.64 fewer years for women with diagnosed ADHD compared with matched women
The authors emphasized that adults with diagnosed ADHD represented only about 0.32% of adults in the dataset, roughly one in nine of the number expected to have ADHD. This means the diagnosed group was highly selected and the estimates should not be treated as the life expectancy of every person with ADHD.
The study also found more diagnosed physical and mental health conditions in the ADHD group. The authors suggested that modifiable risk factors and unmet treatment and health-support needs are likely contributors.
This Is Not Mainly a Male Issue
Older public discussions of ADHD risk have often centered boys and men because ADHD research and diagnosis historically overrepresented males.
The mortality evidence itself does not support describing the life-expectancy problem as primarily male.
In the 2025 UK study, the estimated life-expectancy gap was larger for women than men. O'Nions et al., 2025
A Danish nationwide cohort also found excess mortality associated with ADHD, especially from accidents. After excluding several psychiatric comorbidities, the relative mortality increase was higher in girls and women than in boys and men. Dalsgaard et al., 2015
That does not mean women universally have higher absolute mortality from ADHD. Sex differences vary by sample, age, diagnosis patterns, co-occurring conditions, and cause of death. Women's historical underdiagnosis also makes interpretation harder.
What Seems to Drive the Risk
Across studies, higher mortality in ADHD is especially associated with unnatural causes, including accidents, suicide, and accidental poisoning, although natural-cause mortality may also be elevated in some samples.
A large Swedish cohort found substantially higher premature mortality among people with ADHD, with much of the excess associated with unnatural causes. Psychiatric comorbidity increased risk further. Sun et al., 2019
Other relevant contributors may include:
- injury and accident risk
- suicide risk and co-occurring mental health conditions
- substance-use disorders
- sleep problems
- delayed or fragmented healthcare
- smoking and other health behaviors
- cardiovascular and metabolic conditions
- socioeconomic stress and barriers to treatment
- unmet ADHD treatment and accommodation needs
These factors overlap and should not be treated as a single causal chain.
Treatment May Matter
A 2024 Swedish nationwide observational study of 148,578 people with ADHD found that starting ADHD medication was associated with lower two-year all-cause mortality, particularly mortality from unnatural causes. Medication initiation was associated with a hazard ratio of 0.79 for all-cause mortality and 0.75 for unnatural-cause mortality. Li et al., 2024
This was not a randomized trial, so it cannot prove that medication itself caused the reduction. It does, however, argue against fatalistic interpretations of ADHD mortality data and supports studying treatment access as one potentially modifiable factor.
Do Not Turn These Findings Into a Personal Prediction
Population-level mortality estimates cannot tell an individual person how long they will live.
They identify areas where systems, clinicians, and public-health responses may be missing preventable risk.
A more useful interpretation is that ADHD healthcare should include more than symptom management. It may need attention to:
- mental health and suicide prevention
- substance use
- sleep
- driving and injury prevention
- cardiovascular and metabolic health
- medication access and monitoring
- routine preventive healthcare
- accommodations and environmental fit
- barriers that make healthcare harder to access or sustain
For ADHD Women
The newer evidence makes it especially important not to assume that women with ADHD are protected from the health risks historically discussed in male-heavy ADHD research.
At the same time, women with ADHD are often diagnosed later, and diagnosed samples may disproportionately include people with more complicated clinical histories. That selection effect is one reason the 2025 life-expectancy estimates should be communicated carefully.
Bottom Line
ADHD is associated with increased premature mortality at the population level. The gap appears to involve multiple modifiable health, psychiatric, behavioral, social, and treatment-access factors. It is not evidence that ADHD itself directly shortens every person's life by a fixed number of years, and it is not adequately explained by trauma or chronic stress alone.
Sources
- O'Nions et al., 2025 — Life expectancy and years of life lost for adults with diagnosed ADHD in the UK
- Dalsgaard et al., 2015 — Mortality in children, adolescents, and adults with ADHD
- Sun et al., 2019 — Psychiatric comorbidity and premature death in ADHD
- Li et al., 2024 — ADHD pharmacotherapy and mortality